Feb 23 |
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
|
Feb 21 |
Institutional owners may take dramatic actions as TG Therapeutics, Inc.'s (NASDAQ:TGTX) recent 6.8% drop adds to one-year losses
|
Feb 20 |
Will TG Therapeutics (TGTX) Report Negative Q4 Earnings? What You Should Know
|
Feb 20 |
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
|
Feb 16 |
How Is The Market Feeling About TG Therapeutics?
|
Feb 8 |
TG Therapeutics: Inferred Expectations Point To Undervalued Shares
|
Jan 23 |
TG Therapeutics: Indications Of Slowing Market Growth For Briumvi
|
Jan 22 |
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
|
Jan 19 |
Looking Into TG Therapeutics's Recent Short Interest
|
Jan 11 |
HC Wainwright & Co. Maintains Buy Rating for TG Therapeutics: Here's What You Need To Know
|